• Bachem signed a large-volume peptide supply agreement, triggering a planned expansion at its Sisslerfeld greenfield site in Switzerland.
• Investment set at more than CHF 500 million, supported by prepayments and long-term customer commitments.
• Commercial production at Sisslerfeld expected to start in 2030.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bachem Holding AG published the original content used to generate this news brief on July 21, 2026, and is solely responsible for the information contained therein.